94425-22-6

Usage

Main properties

1. Chemical compound belonging to the class of aminotetralins
2. Derived from dopamine
3. Acts as a selective serotonin receptor agonist
4. Targets 5-HT1A and 5-HT1B receptors
5. Studied for potential pharmacological properties

Specific content

1. Potential antidepressant and anxiolytic effects
2. Investigated for potential use in treatment of substance use disorders
3. Investigated as a neuroprotective agent
4. Unique chemical structure
5. Promising candidate for further research and development of therapeutic applications

InChI:InChI=1/C10H13NO/c11-8-4-5-9-7(6-8)2-1-3-10(9)12/h1-3,8,12H,4-6,11H2

Upstream product

• 1063963-53-0 (6R)-6-[benzyl(methyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol 
• 32940-15-1 5-methoxy-2-tetralone 
• 4018-91-1 2-Amino-5-methoxy-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments

The present invention relates to heterocyclyl-substituted-tetrahydro-naphtalen-amine compounds of general formula (I) methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals, mediated by the 5-HT7 receptor affinity.

Combination of a 5-HT7 receptor ligand and an opioid receptor ligand

The present invention refers to a combination of a 5HT7 receptor ligand and an opioid recptor ligand, especially of a 5HT7 receptor agonist and an opioid recptor agonist, a medicament comprising this combination, or the use of this combination for the treatment of the symptoms of pain, the prevention or the prophylaxis of the symptoms of pain.

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.

A series of 2-aminotetralins, substituted with a methoxy or a hydroxy group on the 5- or 7-position, and with varying N-alkyl or N-arylalkyl substituents, were prepared and evaluated in binding assays for human dopamine (DA) D2, D3, and D4 receptors. Some members of this series were prepared in former studies, but were never tested in vitro with single receptor subtypes, and these were examined again. None of the tested 2-aminotetralins showed high affinity for the dopamine D4 receptor. However, a number of the 2-aminotetralins showed high affinity for both the D2 and the D3 DA receptors, as exemplified by compounds 11-15 and 21-26, while some had a reasonable selectivity for the DA D3 receptors. The affinities of the 2-aminotetralins for the D21, receptor depended on the type of radioligand (agonist or antagonist) used. The agonist affinity data, obtained by using the agonist ligand [3H]N-0437, are thought to be more relevant for calculating DA receptor subtype selectivity.